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 1 
The CD45lowCD271high cell prevalence in bone marrow samples may provide a useful 1 
measurement of the bone marrow quality for cartilage and bone regenerative therapy 2 
 2 
Abstract 3 
Background  4 
Bone marrow (BM) aspirates/concentrates are increasingly used for musculoskeletal 5 
regenerative therapies providing bone and cartilage progenitors. However, the quality of 6 
these BM samples remains imprecise within the clinical settings. As there is an urgent need 7 
for the development of these therapies, a method to count CD45lowCD271high cells was 8 
optimised and tested as an indicator of BM sample quality. 9 
 10 
Methods  11 
BM aspirates were collected from 54 donors (28 males and 26 females, median age: 48). The 12 
reagent concentrations were optimized for a fast staining and Attune flow-cytometer was used 13 
enabling an automated CD45lowCD271high cell counting in BM aspirates, BM concentrates and 14 
those loaded onto a collagen scaffold. The CD45lowCD271high cell numbers were compared to 15 
those obtained using another flow-cytometry (LSRII)-based method and to connective tissue 16 
progenitor (CTP) numbers counted using the colony forming unit-fibroblast (CFU-F) assay.   17 
 18 
 Results 19 
The optimised method enabled the counting of CD45lowCD271high cells within only 15 minutes. 20 
The quantified cell numbers (median: 1,520, range: 96-20,992 cells/ml of BM) were positively 21 
correlated with the CTP counts (p<0.0001, r=0.7237). In agreement with CFU-F and LSRII-22 
based assays, the CD45lowCD271high cell numbers counted using the Attune-based method 23 
were evidently decreasing with age in females but not males (p=0.0015 and p=0.3877 24 
respectively). A significant increase of CD45lowCD271high cell numbers was detected 25 
 3 
following BM concentration (mean: 5-fold, CI: 3.6-7.2). Additionally, the CD45lowCD271high 26 
cell numbers attached to the scaffold were positively correlated with progenitor cell 27 
numbers survived on the scaffold after 2-week culture (p=0.0348). 28 
 29 
Conclusions 30 
An assay counting CD45lowCD271high cells may provide a useful measurement of the BM 31 
quality. While the specificity of this measurement for CTPs remains low in our 32 
experimental conditions, CD45lowCD271high counts are positively and modestly correlated with 33 
the prevalence of CTPs. 34 
 35 
Clinical Relevance 36 
A fast and automated assessment of the BM aspirate/concentrate quality using 37 
CD45lowCD271high cell counting can be a useful tool for the regenerative therapy 38 
improvement. 39 
 40 
 41 
 42 
 43 
 44 
 45 
 46 
 47 
 48 
 4 
Introduction 49 
 50 
The field of regenerative medicine is constantly evolving with new approaches for cartilage 51 
and bone healing dominating both clinical and research activities. Targeting the 52 
environment of non-united fractured bone or degenerative joint with biological modifiers 53 
such as progenitor cells and/or growth factors represent promising therapeutic strategies (1-4). 54 
The rationale behind these strategies is that repopulation of cartilage and bone defects is 55 
possible, as long as the progenitor cells are present. For example, the potential efficacy of the 56 
micro fracture technique for cartilage repair in osteoarthritis (OA) could be related to the 57 
effect of the subchondral bone progenitors that produce growth factors and tissue matrix 58 
helping cartilage repair (5). Furthermore, the use of BM progenitors with or without platelet 59 
rich plasma has been demonstrated to aid bone repair in pre-clinical and clinical studies of the 60 
osteochondral defects, metaphyseal bone defects and femoral head avascular necrosis (AVN) 61 
(6-10).   62 
 Previous research has proven the clinical value of BM aspirates/concentrates 63 
showing a positive correlation between the numbers of applied BM progenitors and 64 
favourable clinical outcomes in tibia fracture non-union (11), hip osteonecrosis (12), OA 65 
(13) and AVN therapy (14-16). Despite the advantages of using BM aspirates or concentrates, 66 
the quality of these samples remains difficult to assess and is poorly controlled. Furthermore, 67 
the numbers of progenitor cells in BM aspirates are widely variable depending on the aspiration 68 
site, volume and surgical technique (17, 18), as well as donor-related factors such as age and 69 
gender (19). Determination of the quality of BM samples is crucial in order to optimize clinical 70 
outcomes, cost and time associated with cell-based therapies. The colony forming unit-fibroblast 71 
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(CFU-F) assay facilitates the counting of connective tissue progenitors (CTPs) and is 72 
commonly used as an indicator for BM sample quality (20, 21), however it usually takes several 73 
days to be informative. CTPs represent the progenitors in native tissues that are able to form 74 
colonies in vitro. However, the CTP concentration and prevalence can be influenced by BM 75 
processing methods. The efficiency of colony formation (the likelihood that a viable CTP 76 
will form a colony when placed into CFU-F assay) is also dependent on culture conditions 77 
(18, 22). 78 
The aim of the current study was to introduce a fast and automated method with 79 
minimum sample processing that helps to indicate the quality of BM aspirates and concentrates. 80 
BM cells isolated based on the CD45lowCD271high phenotype are known to express CD73, CD90 81 
and CD105, but not hematopoietic lineage markers and generate cultures of multipotential 82 
stromal cells fully consistent with the international society for cellular therapy (ISCT) criteria 83 
(23-25).  Importantly, several groups have reported that no colony-forming cells are 84 
present in CD271-negative fraction of BM cells and the detected BM colony-forming activity 85 
was completely confined to the CD45lowCD271high cells (25-31). Therefore, we chose to 86 
quantify in a flow-cytometry based assay, the numbers of CD45lowCD271high cells to assess the 87 
quality of BM aspirates and concentrates. We hope that the work carried out will contribute 88 
WRWKHVWDQGDUGL]DWLRQRIWKHUDSLHVVHWWLQJWKUHVKROGVEHWZHHQµVXFFHVV¶DQGµIDLOXUH¶RIthe 89 
musculoskeletal regenerative therapies.  90 
 91 
Materials and Methods 92 
 93 
Bone marrow aspirates  94 
 6 
BM samples from 54 donors were used for this study under ethical approval, ***Blinded by 95 
JBJS***. The donors were admitted at ***Blinded by JBJS*** for orthopaedic surgery, but did 96 
not have any systemic illness, cancer or metabolic diseases. The donors were 28 males and 26 97 
females with an age range, 22-80 years and median of 48 years. Two groups of patient samples 98 
were used as described in Table 1. All BM aspirates were consistently harvested from the same 99 
location (zone 6) of posterior iliac crest as previously described (17, 26, 32). Each sample 100 
analysis was carried out on one BM sample harvested from one individual at one-time 101 
point.  102 
 103 
Using flow-cytometry for counting CD45lowCD271high cells 104 
A 100µl volume of whole BM, was stained using a three-marker panel containing 105 
Vybrant® DyeCycle Ruby 2.5mM solution in DMSO (Thermo Fisher Scientific, Waltham, 106 
MA, USA), a DNA-selective dye that only labels the nucleated cells enabling gating out of 107 
RBCs and platelets. Additionally, the panel contained anti-CD45 antibody (V450, clone: HI30, 108 
PRXVH,J*țJPO%'%LRVFLHQFHVDQGDQWL-CD271 antibody (PE, clone: ME20.4-1.H4, 109 
mouse IgG1, concentration: 0.75µg/ml, Miltenyi Biotec Ltd, Surrey, UK). The phenotype 110 
indicating BM progenitor cells (CD45lowCD271high cells) was applied as shown previously 111 
(18). The manufacturer recommendation for CD45 and CD271 antibodies was 15 minutes at 112 
room temperature (RT) and for Vybrant DyeCycle Ruby dye, at 37°C for 15 minutes. 113 
However, the antibody/dye staining was optimised to count CD45lowCD271high cells within the 114 
shortest time (described in the results). An acoustic focusing flow-cytometer, Attune® (Thermo 115 
Fisher Scientific) was used allowing an automated cell counting.  For some experiments, the 116 
CD45lowCD271high cell numbers were counted using our previously published flow-cytometry 117 
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based method (18). Briefly, this method involved BM sample staining (using CD90, CD271 and 118 
CD45), red blood cell (RBC) lysis then adding CountBright absolute counting beads (Thermo 119 
Fisher Scientific). The data acquisition was performed using LSRII (BD biosciences).  120 
 121 
Colony Forming Unit-Fibroblasts assay 122 
The colony forming unit-fibroblast (CFU-F) assay was employed as described previously (18) to 123 
count CTPs whereby the BM samples were added to StemMACS MSC expansion media 124 
(Miltenyi Biotec) then cultured for 14 days. The colonies were visualised using methylene blue 125 
and counted manually. Each colony was defined as having at least 50 cells (33).  126 
 127 
BM concentration  128 
BM samples (n=15) were concentrated based on the gradient centrifugation using the BioCUE 129 
device (Zimmer Biomet, Warsaw, USA). The BM aspirates were collected into syringes washed 130 
with anticoagulant acetate citrate dextrose (ACD) and loaded into the BioCUE device. From both 131 
pre- and post-concentration fractions, aliquots were analysed for CD45lowCD271high cell and CTP 132 
counts using the Attune-based method and CFU-F assays respectively. Counting of platelets 133 
was performed for some samples (n=10) using an automated haematopoietic cell counter, 134 
Sysmex (Sysmex Ltd, Milton Keynes, UK).   135 
 136 
Loading of BM samples on a collagen scaffold  137 
The BM aspirates were used to load a collagen scaffold, Bio-Gide® (Geistlich Sons Limited, 138 
Manchester, UK). The pre-loading and the remaining post-loading parts of the BM samples were 139 
processed to count CD45lowCD271high cells. Additionally, the BM-loaded scaffolds were cultured 140 
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for 2 weeks and subsequently processed to quantify BM progenitors that survived on the 141 
scaffolds as previously described (22).  Briefly, the scaffolds were digested using 0.25% 142 
collagenase (Stem Cell Technologies, Grenoble, France). As the surface expression of CD271 143 
can be reduced on cultured cells (25), the extracted cells were stained using CD45, CD90 144 
(BioLegend, CA, USA) and CD73 (Miltenyi Biotec) antibodies and counted using the counting 145 
beads.  146 
 147 
Statistical analysis 148 
The statistical analysis and graph preparation were performed using GraphPad Prism software 149 
version 7.0a. The normal distribution of the data was assessed using the Shapiro-Wilk normality 150 
test and the appropriate test for the data analysis was applied accordingly. The statistical 151 
significance was considered when p value < 0.05. 152 
 153 
Source of Funding 154 
 155 
***Blinded by JBJS***. The funding sources did not have any role in the study design, sample 156 
collection, data analysis or interpretation.   157 
 158 
Results 159 
 160 
1. Optimisation of marker concentration  161 
The fast staining of BM samples was initially optimised. For anti-CD45 antibody, the 162 
CD45lowCD271high cells counted using 10µl of this antibody was higher compared to 5µl 163 
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(p=0.0486), but with no difference between using 10µl and 20µl (p=0.3969), (Figure 1, A).  164 
Regards anti-CD271 antibody, the CD45lowCD271high cell numbers quantified using 20µl of the 165 
antibody was significantly higher than using 10µl (p=0.0450), but similar to 40µl (p=0.5443), 166 
(Figure 1, B). Using three different volumes of the Vybrant DyeCycle Ruby dye, the 167 
CD45lowCD271high cell numbers were similar (p=0.1901 and p=0.1140 for 3µl versus 5µl and 168 
10µl versus 5µl respectively), (Figure 1, C). 169 
We next tested the use of CD45 and CD271 antibodies followed by Vybrant DyeCycle 170 
Ruby (two-step staining) versus the addition of all markers in one step. The cell numbers were 171 
not significantly different between one- or two-step staining methods (p=0.6581), (Figure 1, D).  172 
The CD45lowCD271high cell numbers were also similar using different staining temperatures 173 
(p=0.7237, p=0.1261, p=0.3558 for 4°C versus RT, 37°C versus RT and 4°C versus 37°C 174 
respectively), (Figure 1, E). Also, the CD45lowCD271high cell numbers were not significantly 175 
different comparing 5-minute staining versus 10, 5 versus 15 or 10 versus 15 minutes 176 
(p=0.1981, p=0.5028, p=0.7870 respectively), (Figure 1, F).  177 
For each BM sample, the acquisition time on Attune was completed within 10 178 
minutes. An internal control (counting beads) for automated counting was used and both 179 
automated and bead-dependent quantification were comparable (p=0.3750, Figure 1, G). The 180 
data also showed similar cell numbers quantified when BM samples were 5-time or 10-time 181 
diluted compared to undiluted ones (Figure 1, H). Collectively, we optimised an automated 182 
and simple assay of CD45lowCD271high cells within only 15 minutes. 183 
 184 
2. Comparison of the Attune-based assay versus another flow-cytometry and CFU-F assays 185 
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Using the Attune-based method, the median percentage of CD45lowCD271high cells per total 186 
BM cells was 0.016% (95% Confidence Interval (CI): 0.009-0.032%). The absolute counts of 187 
CD45lowCD271high cells had a median of 1,520 cells/ml of BM (CI: 1,056-6,112, range: 96-188 
20,992 cells/ml of BM). 189 
  The results obtained by Attune, LSRII and CFU-F assays were consistent indicating 190 
for example, high or low quality BM samples (Figure 2, A and B). The CD45lowCD271high 191 
cells numbers obtained using Attune were close to those counted using LSRII (median 1,311 192 
and CI: 900-5,533, range: 87-20,471 cells/ml of BM). However, the CD45lowCD271high cell 193 
numbers obtained by Attune were higher than CTPs (median 60, CI: 45-190, range 3-900 194 
CTPs/ml of BM). Interestingly, the CD45lowCD271high cell numbers measured using Attune 195 
were positively, correlated with the data of LSRII (p<0.0001, r=0.9801), (Figure 2, C) and CTPs 196 
(p<0.0001, r=0.7237), (Figure 2, D).   197 
  When the data were analysed in relation to the age and gender of the donors, a clear 198 
pattern of a negative correlation between the CD45lowCD271high cell numbers with donor ageing 199 
was observed in females (p=0.0015, r=-0.6900), (Figure 3, A, left), but not in the males 200 
(p=0.3877, r=-0.2102), (Figure 3, B, left). This was consistently detected using the LSRII-based 201 
method (females: p=0.0070, r=-0.6563, Figure 3, A, middle and males: p=0.3708, r=-0.2577, 202 
Figure 3, B, middle) and CFU-F assays (females: p=0.0055, r=-0.6904, Figure 3, A, right and 203 
males: p=0.1461, r=-0.4093, Figure 3, B, right). Altogether, the numbers of CD45lowCD271high 204 
cells were comparable between Attune and LSRII and positively correlated with the CTP 205 
counts. 206 
 207 
3. The assessment of CD45lowCD271high cells in BM concentrates  208 
 11 
Our optimisation results showed that the quantified CD45lowCD271high cell numbers in BM 209 
concentrates were generally higher after 10-time dilution compared to 5-time dilution and non-210 
dilution (Figure 4, A) thus 10-time dilution of BM concentrates is needed to ensure accurate 211 
estimation.  The CD45lowCD271high cell numbers were increased significantly after BM 212 
concentration (p<0.0001), (Figure 4, B). The fold increase of the CD45lowCD271high cell numbers 213 
(mean: 5-fold, CI: 3.6-7.2) and that of CTPs (mean: 4.6-fold, CI: 3.1-6) were comparable 214 
(p=0.1894, Figure 4, C). The Sysmex results showed an increase of the platelet numbers in BM 215 
concentrates (p=0.6255) with a mean increase of 4.5-fold (CI: 3-6), (Figure 4, D). In summary, 216 
we have shown a fast assessment of increased CD45lowCD271high cell numbers in the BM 217 
concentrates. 218 
 219 
4. The assessment of CD45lowCD271high cells attached to a collagen scaffold 220 
We used BM aspirates to load Bio-Gide scaffold then the number of attached CD45lowCD271high 221 
cells was calculated by counting these cells in the pre- and post-loading samples (Figure 5, A). 222 
The numbers of CD45lowCD271high cells attached to Bio-Gide were variable between samples, 223 
but consistently dependent on the pre-loading cell quantities (Figure 5, B). Furthermore, the 224 
numbers of attached CD45lowCD271high cells strongly correlated with those survived on Bio-Gide 225 
(p=0.0348, r=0.8434), (Figure 5, C). The CD45lowCD271high cell assessment helped to detect the 226 
donor-related differences in cell attachment onto scaffolds.  227 
 228 
Discussion 229 
 230 
 12 
Bone marrow samples contain CTPs that are potentially useful in treating degenerative 231 
musculoskeletal diseases and non-united bone fractures. The processing of BM samples 232 
helps to concentrate these CTPs. However, the concentration and prevalence of CTPs vary 233 
widely between individuals and according to different aspiration locations and techniques 234 
(17-19). The gold standard CFU-F assay requires at least 6 days (19) thus clinicians 235 
currently have no way of knowing at the time of the procedure, the quality of the BM 236 
sample utilised.  It would be desirable, therefore to have a rapid measurement that could 237 
provide an insight into BM quality on the day of procedure. Here, we introduced a fast and 238 
automated assessment of CD45lowCD271high cells in BM preparations that may be used to 239 
judge the quality of BM samples. This assay was compared to another more time-240 
consuming flow-cytometry assay using LSRII (18) and provided a similar range of 241 
CD45lowCD271high cells. Both assays confirmed an age-related decline in CD45lowCD271high 242 
cells in females but not males as previously reported for CTPs (19).  243 
The specificity of the CD45lowCD271high cell measurement compared to CTP 244 
numbers was low (0.05 on average) i.e. 20 times more CD45lowCD271high cells than CTPs 245 
measured by CFU-F. This finding agrees with previous studies (18, 27). However, the 246 
CD45lowCD271high counts were positively and modestly correlated with the prevalence of 247 
CTPs (r=0.7237). This low specificity does not prevent the use of this assay for estimating of 248 
aspirate quality, however it is clear that it does not enable exact measurement of CTP 249 
numbers. This might be related to the senescence of some CD45lowCD271high cells in culture 250 
during CFU-F assay as a result of plating at very low clonal densities. Another possible 251 
explanation for this disparity is that CTPs represent only a subset of the CD45lowCD271high 252 
population as suggested recently (34). It is possible that with the addition of more markers, 253 
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this subpopulation could be defined allowing increased specificity of the assay. In one 254 
study, CD146 marker was tested, but no further enrichment in CTP numbers was detected 255 
in the CD146+CD271+ fraction compared to CD146-CD271+ fraction (27). Subsequently, the 256 
same group showed that the majority of CTPs resided in the CD140a-CD271+ fraction (29) 257 
however, our group did not find such a clear subpopulation (35) and we are investigating 258 
this further. Others have not yet devised additional, more selective markers while all agree 259 
on the value of CD271 (36).  260 
We believe the assessment of CD45lowCD271high cells has a very high sensitivity 261 
(close to 100%) as other studies have shown that all BM colony-forming activity is confined 262 
to CD45lowCD271high cells and CD271-negative cells did not have any colony forming ability 263 
(25-31). The implications of this assay with high sensitivity and relatively low specificity is 264 
that no CTPs are missed out while some progenitor cells with potentially lower colony 265 
forming capacity than detected in our experimental conditions can be counted.  266 
The CFU-F assay data can be varied depending on the patient age and BM 267 
aspiration site and volume (18, 22). This could explain that CTPs numbers in this study 268 
showed some variability from previous work (37). Using various BM processing methods 269 
could have an additional effect on variability of CTP counts e.g. using lymphoprep causes 270 
CTP loss (38).  We have ensured optimal and consistent culture conditions by using 271 
complete and batch-tested media for CFU-F assays. Thus, the possibility of 272 
underestimation of CTPs is small but still exists.  273 
The BM aspirates or concentrates loaded on scaffolds have been demonstrated to enhance 274 
cartilage repair in OA knee or hip (39-41), focal condylar lesions of knee articular cartilage and 275 
talar osteochondral injuries with promising outcomes (10, 42). The results presented here have 276 
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demonstrated that the CD45lowCD271high cell numbers were increased 5-fold after BM 277 
concentration. We also reported that platelets were concentrated 4.5-fold showing an additional 278 
value of un-fractioned BM concentrates via providing growth factors (43). Compared to our 279 
data, Dawson et al showed 4-fold increase of CTPs in BM concentrates (44).  Another recent 280 
study has shown that two different concentrator devices produced significantly different numbers 281 
of CTPs and dissimilar levels of growth factors (45). Our data also showed that the numbers of 282 
attached CD45lowCD271high cells onto Bio-Gide were variable depending on the initial cell 283 
counts in the BM samples. Collectively, this further emphasises the potential value of 284 
CD45lowCD271high cell count assessment to indicate the quality of BM samples after 285 
concentration or when loaded onto scaffolds. 286 
In conclusion, our aim was to report on a method that can help to indicate the 287 
µSRWHQF\/quality¶RIWKH%0VDPSOHDSSOLHG in clinical settings. The quantitative assessment 288 
of CD45lowCD271high cells in BM aspirates can be performed rapidly and the numbers of 289 
CD45lowCD271high cells are positively correlated with the numbers of CTPs. While the 290 
specificity of CD45lowCD271high cell assessment is low compared to CFU-F assay, the 291 
sensitivity of this method is very high.  Since the CFU-F data cannot be immediately 292 
available on the day of surgery, these findings support the view that an assay measuring 293 
CD45lowCD271high cells could be useful as a surrogate measure of BM quality on the day of 294 
surgery, if that information were available. Future studies on the rapid measure of CTP 295 
prevalence in BM samples with inclusion of other specific markers are desirable to further 296 
enhance the method described in this study.297 
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Figure legends 479 
Figure 1: Optimisation of the staining and counting of CD45lowCD271high cells on Attune flow-480 
cytometer 481 
The CD45lowCD271high cell numbers quantified using 3 different volumes of anti-CD45 and 482 
CD271 antibodies and Vybrant DyeCycle Ruby (VDR) dye, were compared (6WXGHQW¶V paired t-483 
test, n=10 samples), (A, B, C).  The comparison was performed between CD45lowCD271high cell 484 
numbers counted using the one-step versus two-VWHSVWDLQLQJ6WXGHQW¶VSDLUHGW-test, n=6 485 
VDPSOHV'DWGLIIHUHQWVWDLQLQJWHPSHUDWXUHV6WXGHQW¶VSDLUHGW-test, n=7 samples), (E) and 486 
after 5-, 10- and 15-PLQXWHVWDLQLQJ6WXGHQW¶VSDLUHGW-test, n=10 samples), (F).  The comparison 487 
of CD45lowCD271high cell numbers enumerated on Attune using automated counting versus 488 
counting beads (Wilcoxon matched-pairs signed rank test, n=9 samples), (G). The 489 
CD45lowCD271high cell numbers were counted in BM aspirates that were stained either undiluted, 490 
5-time or 10-time diluted (n=5 samples, S: sample), (H).  491 
 492 
Figure 2: The CD45lowCD271high cell numbers detected by the Attune versus LSRII-based 493 
method and CTP numbers. 494 
The CD45lowCD271high cell numbers counted using Attune were compared to those obtained by 495 
another flow-cytometry method using LSRII and CTP numbers. Examples of high-quantity (A) 496 
and low-quantity (B) BM progenitor samples were shown. The correlation was analysed between 497 
CD45lowCD271high cell numbers quantified on Attune versus LSRII-based method (n=33 498 
samples), (C) or CTPs using CFU-F assay (n=33 samples), (D). Spearman r test was used for the 499 
correlation analysis. 500 
 501 
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Figure 3: The numbers of CD45lowCD271high cells and CTPs in the BM samples of different age 502 
and gender donors.   503 
The correlation between the numbers of CD45lowCD271high cells and ageing in females (A) and 504 
males (B) are shown. The results of the two methods for counting of CD45lowCD271high cells 505 
(using Attune and LSRII-based) and CTP numbers using CFU-F assay were compared.  For 506 
females (A), 18, 16 and 15 samples were included respectively.  For males (B), 19, 14 and 14 507 
samples were used respectively. Spearman r test was used for the correlation analysis. 508 
 509 
Figure 4: The assessment of CD45lowCD271high cells in BM concentrates.  510 
The samples of BM concentrates were either undiluted, 5-time or 10-time diluted then was used 511 
to count CD45lowCD271high cells (n=8 samples, S: sample), (A). The numbers of 512 
CD45lowCD271high cells were compared between pre- and post-concentration (Conc) samples 513 
(Wilcoxon matched-pairs signed rank test, n=15 samples), (B). The fold increase of 514 
CD45lowCD271high cell numbers was compared versus CTPs after BM concentration 515 
6WXGHQW¶VSDLUHGW-test, n=13 samples), (C). The fold increase of CD45lowCD271high cells 516 
(calculated using the Attune-based method) and platelets (calculated using Sysmex) was 517 
compared after BM concentration. The figure showed the mean with 95% CI (Unpaired t-test, 518 
n=15 sample for CD45lowCD271high cells and n=10 samples for platelets), (D).  519 
 520 
Figure 5: The assessment of CD45lowCD271high cells attached to Bio-Gide scaffold. 521 
The number of CD45lowCD271high cells attached to Bio-Gide was calculated by counting these 522 
cells in pre- and post-loading (remaining) BM samples (A). The numbers of pre-loading 523 
CD45lowCD271high cells and those attached to Bio-Gide were shown (n=6 samples, S: sample), 524 
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(B). The correlation was analysed between the number of CD45lowCD271high cells attached to 525 
Bio-Gide and the progenitor cells (CD45-CD90+CD73+) survived on Bio-Gide after 2-week 526 
culture (Pearson r test, n=6 samples), (C). 527 
